^
Association details:
| Biomarker: | EGFR negative + ALK negative |
|---|---|
| Cancer: | Lung Non-Squamous Non-Small Cell Cancer |
| Drug: | Tyvyt (sintilimab) (PD1 inhibitor) + Fruzaqla (fruquintinib) (VEGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
145P - Preliminary results of a phase ? study of fruquintinib combined with sintilimab and chemotherapy as the first-line treatment in advanced naive EGFR- and ALK-negative non-squamous non-small cell lung cancer(nsq-NSCLC)
Published date:
12/01/2022
Excerpt:
This single-arm, open-label, phase II study (NCT04956146) consists of a safety lead-in phase(Part 1) and dose expansion phase(Part 2)....Of 9 evaluable pts, ORR and DCR were 66.7% and 100%(6 partial response and 3 stable disease)….This finding showed promising efficacy for fruquintinib combined with sintilimab and chemo in pts with advanced NSCLC as first-line treatment with a manageable safety profile. These findings support fruquintinib plus sintilimab and chemo as a potential new first-line treatment option for unresectable or metastatic advanced naive EGFR- and ALK-negative nsq-NSCLC.
Trial ID:
